Chemistry and pharmacological diversity of quinoxaline motifs as anticancer agents-Reference-Cited by-同舟云学术

Chemistry and pharmacological diversity of quinoxaline motifs as anticancer agents

Published:2019-03-28 Issue:2 Volume:69 Page:177-196
ISSN:1846-9558
Container-title:Acta Pharmaceutica
language:en
Short-container-title:

Author:

Ajani Olayinka O.¹,Nlebemuo Martins T.¹,Adekoya Joseph A.¹,Ogunniran Kehinde O.¹,Siyanbola Tolutope O.¹,Ajanaku Christiana O.¹

Affiliation:

1. Department of Chemistry Covenant University , CST, Canaanland Km 10 Idiroko Road, P.M.B. 1023 , Ota Ogun State, Nigeria

Abstract

Abstract Surpassing heart diseases, cancer is taking the lead as the deadliest disease because of its fast rate of spreading in all parts of the world. Tireless commitment to searching for novel therapeutic medicines is a worthwhile adventure in synthetic chemistry because of the drug resistance predicament and regular outbreak of new diseases due to abnormal cell growth and proliferation. Medicinal chemistry researchers and pharmacists have unveiled quinoxaline templates as precursors of importance and valuable intermediates in drug discovery because they have been established to possess diverse pharmacological potentials. Hence, this review highlights the current versatile routes to accessing functionalized quinoxaline motifs and harnessing their documented therapeutic potentials for anticancer drug development.

Publisher

Walter de Gruyter GmbH

Subject

Pharmaceutical Science,Pharmacology,General Medicine

Link

https://www.sciendo.com/pdf/10.2478/acph-2019-0013

Reference108 articles.

1. 1. World Health Organization, Cancer Control: Knowledge into Action. WHO Guide, Geneva 2005; http://www.who.int/cancer; last access date November 27, 2017.

2. 2. M. R. Alison, The Cancer Handbook, Nature Publishing Group, London 2002.

3. 3. M. Shaharyar, M. M. Abdullah, M. A. Bakht and J. Majeed, Pyrazoline bearing benzimidazoles: Search for anticancer agent, Eur. J. Med. Chem. 45 (2010) 114–119; https://doi.org/10.1016/j.ejmech.2009.09.03210.1016/j.ejmech.2009.09.032

4. 4. K. M. Amin, M. M. Ismail, E. Noaman, D. H. Soliman and Y. A. Ammar, New quinoxaline 1,4-di-N-oxides. Part 1: Hypoxia-selective cytotoxins and anticancer agents derived from quinoxaline 1, 4-di-N-oxides, Bioorg. Med. Chem. 14 (2006) 6917–6923; https://doi.org/10.1016/j.bmc.2006.06.03810.1016/j.bmc.2006.06.038

5. 5. A. Courbet, N. Bec, C. Constant, C. Larroque, M. Pugniere, S. E. Messaoudi, Z. Zghaib, S. Khier, C. Deleuze-Masquefa and F. Gattacceca, Imidazoquinoxaline anticancer derivatives and imiquimod interact with tubulin: Characterization of molecular microtubule inhibiting mechansims in correlation with cytotoxicity, PLoS ONE12 (2017) e0182022; https://doi.org/10.1371/journal.pone.018202210.1371/journal.pone.0182022

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. CADD Methods for Developing Novel Compounds Synthesized to Inhibit Tyrosine Kinase Receptors;Current Topics in Medicinal Chemistry;2024-08-07

2. [MTP−IL] as Mesoporous Heterogeneous Organocatalyst for the One‐Pot Synthesis of Indeno [1,2‐b] Quinoxalin‐11‐Ylidenamine Derivatives: A Green, Sustainable, and Metal‐Free Protocol;ChemistrySelect;2024-07-16

3. Inhibition of protein misfolding and aggregation by steroidal quinoxalin-2(1H)-one and their molecular docking studies;International Journal of Biological Macromolecules;2024-06

4. Highly Efficient Photoinitiation Systems Based on Dibenzo[a,c]phenazine Sensitivity to Visible Light for Dentistry;Materials;2024-05-28

5. Quinoxaline derivatives: Recent discoveries and development strategies towards anticancer agents;European Journal of Medicinal Chemistry;2024-05